Absci (NASDAQ:ABSI) Posts Earnings Results, Meets Expectations

Absci (NASDAQ:ABSI) announced its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19), FiscalAI reports. Absci had a negative net margin of 7,756.38% and a negative return on equity of 61.71%. The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.66 million.

Here are the key takeaways from Absci’s conference call:

• Absci expects to report interim 13-week pattern hair loss data in December 2026 and full 26-week proof-of-concept data in early 2027. Management characterized the interim readout as directional and said it will not change the ongoing trial.
• The company said blinded aggregate data to date show ABS-201 is well tolerated, and its estimated half-life may support two or three injections over six months. These findings are preliminary and do not yet establish efficacy.
• Absci now anticipates starting its planned phase II endometriosis trial in mid-2027, with doses to be selected after reviewing HEADLINE trial data. The company estimates the program could reach more than $4 billion in peak sales if development succeeds.
• Cash, cash equivalents and marketable securities totaled $173.7 million at quarter-end, down from $201.1 million at June 30; management expects funding to last into the second half of 2028. Quarterly R&D expenses rose to $23.6 million from $19.2 million a year earlier, while SG&A increased to $9 million from $8.4 million.
• Management cited consumer research suggesting that 30–35 additional target-area hairs per square centimeter at 26 weeks could support strong adoption, and estimated a $25 billion U.S. pattern hair loss market. These are company estimates based on hypothetical product profiles, not clinical results.

Absci Stock Performance

NASDAQ ABSI opened at $8.90 on Friday. The stock has a market cap of $1.53 billion, a P/E ratio of -11.12 and a beta of 2.22. Absci has a fifty-two week low of $2.24 and a fifty-two week high of $12.54. The stock has a 50 day simple moving average of $9.66 and a two-hundred day simple moving average of $6.78.

Top Absci Stories

These are some of the ABSI stories that stood out recently:

• Positive Sentiment: Needham raised its price target to $15 from $11 and maintained a Buy rating. BTIG also reaffirmed its Buy rating, with a $16 target. The higher targets signal analyst confidence in Absci’s prospects. Needham rating BTIG rating
• Positive Sentiment: The company appointed Gerry Muhle, whose past roles include Galderma, Allergan and GSK, as chief commercial officer to help prepare for potential product launches and develop its pipeline. Chief commercial officer appointment
• Neutral Sentiment: Absci reported $173.7 million in cash, equivalents and marketable securities, which it expects to fund operations into the second half of 2028. It also plans a Phase 2 trial of ABS-201 for endometriosis in mid-2027. Q3 earnings call highlights

Wall Street Analyst Weigh In

Several research firms have issued reports on ABSI. HC Wainwright restated a “buy” rating on shares of Absci in a research report on Tuesday, October 20th. Needham & Company LLC raised their price objective on Absci from $11.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday. Guggenheim reiterated a “buy” rating on shares of Absci in a report on Monday, September 28th. Jefferies Financial Group began coverage on Absci in a research note on Thursday, October 29th. They issued a “buy” rating and a $14.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Absci in a research note on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

About Absci

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.